Timing of local treatment for limited metastatic stomach or esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving local treatments (like surgery or radiation) to cancer spots later—after starting immunotherapy or targeted therapy—helps people with stomach or esophageal cancer that has spread to a few places. It aims to improve outcomes by timing treatments carefully.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a limited number of cancer spots (metastases) that can be treated with surgery or radiation.
- Your tumor has a marker like PD-L1, HER2, or Claudin 18.2 that allows you to receive immunotherapy or targeted therapy.
- You have not had any prior chemotherapy or other systemic treatment for cancer that has spread.
- You are healthy enough to undergo both local treatments and systemic therapy for at least 18 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that combines chemotherapy with immunotherapy, followed by surgery, for people whose esophageal or stomach cancer has spread to a few areas (oligometastatic). The goal is to see if this approach can shrink the cancer and improve outcomes.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can improve outcomes for patients with a certain type of stomach or esophageal cancer that can be surgically removed. It aims to see if this approach shrinks tumors and helps prevent recurrence.
This trial tests a new approach for locally advanced stomach cancer. It uses a heated chemotherapy bath (HIPEC) before giving a combination of two chemotherapy drugs (SOX or XELOX) plus an immunotherapy drug called serplulimab. This aims to shrink the tumor and improve the chances of successful surgery and long-term control.
This trial tests a combination of chemotherapy drugs and an immunotherapy drug given before surgery for stomach cancer in younger patients. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether adding targeted radiation or other local treatments can help people with esophageal cancer that has spread to only a few spots (up to 4) after they've been treated with a PD-1 inhibitor. It aims to control the cancer better and improve outcomes.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.